Skip to content
Head to head

Exelixis vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: EXEL · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

EXEL +52.4%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
EXELVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price64.63515.02
Change today-1.82%-1.08%
1-year return+54.7%+22.0%
Market cap$15.77B$130.58B
52-week range39.71 – 73.69412.27 – 568.67
Valuation
P/E (TTM)19.3533.14
P/E percentile, own 5-yr range32nd99th
P/B8.606.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)2.7815.32
Net profit (TTM)$678.35M$3.88B
Revenue (TTM)$2.50B$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+10.2%+11.8%
Gross margin96.3%85.5%
Operating margin40.2%33.1%
Net margin35.5%30.7%
Free cash flow (TTM)$1.14B$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership103.2%96.8%
Insider activity (12mo)17 buy / 33 sell28 buy / 22 sell
Short interest (% of float)10.5%1.9%
Analyst consensus57% buy / 29% hold / 14% sell (7)95% buy / 5% hold (21)
Analyst price target$65 (+1%)$624 (+21%)
StockVane view
StockVane Quant RatingC (89)C (68)
Company
Employees4,6006,400
Founded19941989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.